𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pegylated interferon for chronic hepatitis C in children affects growth and body composition: Results from the pediatric study of hepatitis C (PEDS-C) trial

✍ Scribed by Maureen M. Jonas; William Balistreri; Regino P. Gonzalez-Peralta; Barbara Haber; Steven Lobritto; Parvathi Mohan; Jean P. Molleston; Karen F. Murray; Michael R. Narkewicz; Philip Rosenthal; Kathleen B. Schwarz; Bruce A. Barton; John A. Shepherd; Paul D. Mitchell; Christopher Duggan

Book ID
112097887
Publisher
John Wiley and Sons
Year
2012
Tongue
English
Weight
285 KB
Volume
56
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Variants in interferon-alpha pathway gen
Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial
✍ Tania Mara Welzel; Timothy R. Morgan; Herbert L. Bonkovsky; Deepa Naishadham; Ru πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 270 KB πŸ‘ 2 views

Combination treatment with pegylated-interferon-alpha (PEG IFN-␣) and ribavirin, the current recommended therapy for chronic hepatitis C virus (HCV) infection, results in a sustained virological response (SVR) in only about half of patients. Because genes involved in the interferon-alpha pathway may

Interferon and ursodeoxycholic acid comb
Interferon and ursodeoxycholic acid combined therapy in the treatmet of chronic viral C hepatitis: Results from a controlled randomized trial in 80 patients
✍ Eveline Boucher; HervΓ© Jouanolle; Patrice Andre; Annick Ruffault; Dominique Guya πŸ“‚ Article πŸ“… 1995 πŸ› John Wiley and Sons 🌐 English βš– 744 KB

Because 70% to 75% of patients with chronic hepatitis C either do not respond to or relapse after interferon (IFN) therapy, and because ursodeoxycholic acid (UDCA) has been shown to reduce aminotransferase lev-TOLOGY 199% 21 :322-327.